Matthew Cooper

Matthew Cooper Email and Phone Number

Chief Executive Officer at Enumera Molecular @ Enumera Molecular
Matthew Cooper's Location
Palo Alto, California, United States, United States
Matthew Cooper's Contact Details
About Matthew Cooper

Matthew Cooper, Ph.D., MBA, is the Chief Executive Officer and Founder of Enumera Molecular, a life science tools company developing a single molecule detection platform capable of rapid, low cost assessment of biomolecules via liquid biopsy. A serial biotech entrepreneur, Matthew has experience starting several successful biotech/diagnostic/data science companies, mediating M&A transactions, IPO, scaling R&D organizations, and overseeing product development from discovery to launch on many commercial products in the life sciences.Matthew serves on the Board of Directors of Avials Medical, in addition to being a mentor to other life science entrepreneurs via StartX and an active Angel investor.Matthew has over 20 years experience in diagnostic, data science, and drug product development. Past areas of specialty have included biomarker discovery and development, data science, bioinformatics, safety (toxicology and DMPK), and organizational/corporate strategy.Matthew's educational background is as diverse as his professional experience with dual MBAs from Columbia Business School (Finance) and the Berkeley Haas School of Business (Entrepreneurship). Matthew also has a Ph.D. in Toxicology (University of Kentucky, College of Medicine) and a B.S. in Chemistry (University of Tulsa, College of Engineering). He is board certified in toxicology (Diplomat of the American Board of Toxicology) and has earned a Certificate of Entrepreneurship from the Berkeley Haas School of Business.In his downtime, Matthew is an avid foodie and wine collector.

Matthew Cooper's Current Company Details
Enumera Molecular

Enumera Molecular

View
Chief Executive Officer at Enumera Molecular
Matthew Cooper Work Experience Details
  • Enumera Molecular
    Chief Executive Officer
    Enumera Molecular Apr 2022 - Present
    Ann Arbor, Michigan, Us
    CEO & Founder of Enumera Molecular, a life science tools company developing a single molecule detection platform capable of rapid, low cost assessment of biomolecules via liquid biopsy.
    View
  • Avails Medical, Inc.
    Board Member
    Avails Medical, Inc. Mar 2019 - Present
    Menlo Park, Ca, Us
    Avails Medical is developing solutions in accurate, rapid, and digital pathogen detection in bodily fluids to indicate effective drug treatments in real-time.For more information, visit https://availsmedical.com
    View
  • Startx.
    Adviser & Mentor
    Startx. Aug 2013 - Present
    Palo Alto, California, Us
    StartX is a collection of serial entrepreneurs, industry experts, tenured Stanford professors, and well-funded growth-stage startups brought together via a non-profit community. We believe that entrepreneurs can achieve more as a group, than we can as individuals. We help our companies hire elite talent, secure funding, and tap into one of the most powerful and innovative networks in the world: the Stanford University Alumni Network and other StartX Founders.For more information, please visit: https://startx.com
    View
  • Neoseq
    Board Member
    Neoseq Nov 2018 - Dec 2022
    NeoSeq is developing advanced technologies and comprehensive services for global healthcare needs, inclduing: ● Complete solution for non-invasive prenatal diagnostics -Lowest cost cell free fetal DNA based screening -Most advanced fetal cell technology for disease confirmation ● Cancer diagnostics -Liquid biopsy analysis through ctDNA and CTC -Early cancer screening ● Health risk assessment -Inherited diseaseshttp://www.neoseqltd.com for more information.
  • Progenity, Inc.
    General Manager, Diagnostics
    Progenity, Inc. Oct 2021 - Apr 2022
    Full responsibility for all aspects of the Diagnostics business unit at Progenity.
  • Progenity, Inc.
    Chief Scientific Officer
    Progenity, Inc. Apr 2015 - Apr 2022
    Primary responsibilities include strategic and operational leadership of the R&D organization, Data Science, and IT. As Chairman of the corporate Portfolio Steering Committee, responsible for building an innovative product portfolio and pipeline, in addition to corporate strategy. During his tenure, Matt has lead an exceptionally productive R&D organization, delivering a robust pipeline of innovative products yielding hundred of millions of dollars in lifetime revenue, including:- Preparent (global carrier screening) 2nd generation and 3rd generation o Significantly expanding content whilst reducing COGS- Riscover o Low COGS, heritable cancer genetic test- Innatal 1 o Internalization of NGS-based NIPT- Innatal 2 o Proprietary NIPT with best-in-class performance and low COGS- Resura o First-in-class monogenic disease detection using maternal blood sample- Preecludia o First-in-class rule-out test for Preeclampsia
  • Preeclampsia Foundation
    Board Member
    Preeclampsia Foundation Mar 2014 - 2020
    Melbourne, Fl, Us
    Member of the board of directors for a national patient advocacy organization, serving over 200,000 pregnany women each year who suffer from hypertensive disorders of pregnancy.
    View
  • Stanford University School Of Medicine
    Advisor At Spark Translational Research Program
    Stanford University School Of Medicine 2011 - 2019
    Palo Alto, Ca, Us
    Evaluate IP from Stanford College of Medicine program for development and commercialization. http://sparkmed.stanford.edu/
    View
  • Ucsf
    Advisor And Mentor To Lean Launchpad For Life Sciences & Healthcare
    Ucsf Aug 2013 - Aug 2018
    San Francisco, California, Us
    Advise Lean LaunchPad faculty on curriculum and business case applications of lean launchpad concepts in the life science industry.Mentor life science start-ups in the Lean LaunchPad program. Assist life start-up founders in commercializing their scientific discoveries via customer development and lean start-up methodologies.http://ita.ucsf.edu/entrepreneurship-center/education/courses/lean-launchpad-life-science-healthcare
    View
  • Carmenta Bioscience
    Ceo And Founder
    Carmenta Bioscience Feb 2012 - Mar 2015
    Acquired by Progenity Apr2015Founder and CEO of Carmenta Bioscience, a biotechnology company dedicated to addressing unmet medical needs in maternal and fetal health, with a focus on development and commercialization of diagnostic tests for preeclampsia. Co-founded by Atul Butte and Bruce Ling from Stanford School of Medicine.Raised >$2M in an oversubscribed seed round (http://www.businesswire.com/news/home/20130807005422/en/Carmenta-Bioscience-Secures-2-Million-Oversubscribed-Seed) and then acquired 18 months later by Progenity (http://www.businesswire.com/news/home/20150429005191/en/Progenity-Acquires-Carmenta-Bioscience-Proprietary-Preeclampsia-Technology).
  • Syapse Inc.
    Chief Science Officer
    Syapse Inc. Feb 2010 - Feb 2012
    San Francisco, Ca, Us
    Responsible for translating customer's scientific and strategic needs into actionable software development goals. Other responsibilities include:• Customer development• Identification and management of strategic partnerships • Corporate strategy• Management of scientific talent
    View
  • Hoffmann-La Roche
    Head Of Non-Clinical Safety Information
    Hoffmann-La Roche Jan 2009 - Apr 2010
    Switzerland 🇨🇭 , Ch
    Responsible for leading all strategic and operational aspects of non-clinical safety information globally. Also responsible for identifying and collaborating with key technology partners in the industry and academia. Reported directly to Global Head of Non-Clinical Safety and served on the Core Global Leadership Team. Matthew also served on the RIST (Roche Informatics Steering Team), a decision making body that governed strategic investments in informatics for Roche Pharma globally.
    View
  • Hoffmann-La Roche
    Principal Research Scientist
    Hoffmann-La Roche Feb 2006 - Jan 2009
    Switzerland 🇨🇭 , Ch
    Discovery & Investigative Safety group with Non Clinical Safety.My job responsibilities are 3-fold: 1. Lead early safety assessments for the therapeutic protein portfolio in Palo Alto. Act as immunosafety coordinator for site (50% effort).2. Lead the development and deployment of informatics strategies to support the Non Clinical Safety department; serve as chair of the Data Management working group for the Critical Path Institute (25% effort).3. Conduct investigational toxicology projects to address safety issues for both biologics and small molecules (25% effort).
    View
  • Biogen Idec
    Scientist Ii
    Biogen Idec Feb 2004 - Feb 2006
    Cambridge, Ma, Us
    Biomarker scientist, also group leader for Transcript Profiling and Computational Biology within Preclinical Development Sciences department.
    View
  • Biogen Idec
    Scientist I
    Biogen Idec Feb 2001 - Feb 2004
    Cambridge, Ma, Us
    Project Toxicologist: worked on development teams to support drug registration activities. Tasks included designing, monitoring, and reporting of nonclinical safety studies, contributing to INDs and end of Phase II documents, and performing toxicogenomic and other investigational safety evaluations.
    View
  • Merrill Lynch
    Summer Intern
    Merrill Lynch May 1999 - Aug 1999
    New York, Ny, Us
    Worked with brokers to create portfolio reports for high wealth clients. Liaised with high wealth clients regarding biotechnology and pharmaceutical companies, providing “plain English” explanations of product pipelines.
    View
  • Dow Corning
    Summer Intern
    Dow Corning Jun 1997 - Aug 1997
    Midland, Michigan, Us
    Established the high-throughput “Ames II” assay for genotoxicity screening. Also cloned human cytochrome P450 enzymes into Ames bacterial strains to assist in the evaluation of human-specific mutagens.
    View
  • Procter & Gamble
    Summer Intern
    Procter & Gamble Jun 1996 - Aug 1996
    Cincinnati, Ohio, Us
    Performed CHO cell chromosomal aberration assay in corporate toxicology group.
    View

Matthew Cooper Education Details

  • Columbia Business School
    Columbia Business School
    General
  • University Of California, Berkeley, Haas School Of Business
    University Of California, Berkeley, Haas School Of Business
    Entrepreneurship
  • University Of Kentucky College Of Medicine
    University Of Kentucky College Of Medicine
    Toxicology
  • The University Of Tulsa
    The University Of Tulsa
    Chemistry (College Of Engineering)

Frequently Asked Questions about Matthew Cooper

What company does Matthew Cooper work for?

Matthew Cooper works for Enumera Molecular

What is Matthew Cooper's role at the current company?

Matthew Cooper's current role is Chief Executive Officer at Enumera Molecular.

What is Matthew Cooper's email address?

Matthew Cooper's email address is co****@****ord.edu

What is Matthew Cooper's direct phone number?

Matthew Cooper's direct phone number is +141521*****

What schools did Matthew Cooper attend?

Matthew Cooper attended Columbia Business School, University Of California, Berkeley, Haas School Of Business, University Of Kentucky College Of Medicine, The University Of Tulsa.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.